As­traZeneca lands FDA ap­proval for AKT in­hibitor in bio­mark­er-de­fined breast can­cer sub­set

As­traZeneca has scored an FDA ap­proval for its AKT in­hibitor capi­vasert­ib, adding a new tar­get­ed ther­a­py to its treat­ment of­fer­ings in breast can­cer.

The drug, with the mar­ket name Truqap, is ap­proved in com­bi­na­tion with As­traZeneca’s own Faslodex (ful­ves­trant) to treat a sub­set of pa­tients with hor­mone re­cep­tor (HR)-pos­i­tive, HER2-neg­a­tive lo­cal­ly ad­vanced or metasta­t­ic breast can­cer who have pro­gressed on at least one en­docrine-based reg­i­men in the metasta­t­ic set­ting or ex­pe­ri­enced re­cur­rence with­in 12 months of com­plet­ing ad­ju­vant ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER